Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy

Malignant pleural mesothelioma (MPM) is a rare neoplasm, generally caused by asbestos exposure. This case details how a patient treated with nintedanib during the LUME‐Meso study was rechallenged with nintedanib. The findings highlight the benefit of nintedanib rechallenge and the potential use of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Grosso, Federica, Roveta, Annalisa, Gallizzi, Giulia, Belletti, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186873/
https://www.ncbi.nlm.nih.gov/pubmed/30349716
http://dx.doi.org/10.1002/ccr3.1775
Descripción
Sumario:Malignant pleural mesothelioma (MPM) is a rare neoplasm, generally caused by asbestos exposure. This case details how a patient treated with nintedanib during the LUME‐Meso study was rechallenged with nintedanib. The findings highlight the benefit of nintedanib rechallenge and the potential use of continuous anti‐angiogenic therapy in MPM treatment.

Ejemplares similares